Cargando…

Therapeutic Vaccine for Lymphoma

The unique antigenic determinants (Idiotype [Id]) of the immunoglobulin expressed on a given B-cell malignancy can serve as a tumor-specific antigen for active immunotherapy. Therapeutic vaccines targeting the tumor-specific idiotype have demonstrated promising results against lymphomas in phase I/I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Seung-Tae, Neelapu, Sattva S., Kwak, Larry W.
Formato:	Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2007
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628002/ https://www.ncbi.nlm.nih.gov/pubmed/17326239 http://dx.doi.org/10.3349/ymj.2007.48.1.1

Ejemplares similares

Therapy of newly diagnosed follicular lymphoma
por: Westin, Jason R., et al.
Publicado: (2012)

Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
por: Chu, Fuliang, et al.
Publicado: (2014)

Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol
por: Thomas, Sheeba K., et al.
Publicado: (2018)

Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma
por: Chen, Zheng, et al.
Publicado: (2013)

First-in-human clinical trial of personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma
por: Kwak, Larry, et al.
Publicado: (2023)

Hodgkin Lymphoma Untreated for Six Years Presenting with Tracheoesophageal Fistula
por: Westin, Jason R., et al.
Publicado: (2012)

Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment
por: Zhang, Han, et al.
Publicado: (2016)

Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma
por: Gribben, John, et al.
Publicado: (2023)

CXCR5+CD8+ T cells are localized in B cell follicles and germinal centers and exhibit regulatory and anti-tumor function
por: Chu, Fuliang, et al.
Publicado: (2015)

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
por: Morris, Emma C., et al.
Publicado: (2021)

COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients with Current or Prior Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT
por: Lane, Deanna L, et al.
Publicado: (2021)

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma
por: Yoshimura, Mariko, et al.
Publicado: (2014)

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets
por: Malyguine, Anatoli, et al.
Publicado: (2004)

Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma
por: Sarkar, Aloke, et al.
Publicado: (2015)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

ABCG2 is a Direct Transcriptional Target of Hedgehog Signaling and Involved in Stroma-Induced Drug Tolerance in Diffuse Large B-Cell Lymphoma
por: Singh, Rajesh R, et al.
Publicado: (2011)

Immortalized B Cells Transfected With mRNA of Antigen Fused to MITD (IBMAM): An Effective Immunological Tool for In-Vitro Immune-Monitoring of Antigen-specific T Cells
por: Zhang, Tiantian, et al.
Publicado: (2022)

Targeting Wnt pathway in mantle cell lymphoma-initiating cells
por: Mathur, Rohit, et al.
Publicado: (2015)

Immortalized B Cells Transfected with mRNA of Antigen Fused to MITD (IBMAM): An Effective Tool for Antigen-Specific T-Cell Expansion and TCR Validation
por: Wang, Zhe, et al.
Publicado: (2023)

Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
por: Fang, Penny Q., et al.
Publicado: (2021)

Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients
por: Foglietta, Myriam, et al.
Publicado: (2012)

Targeting B cell malignancies through human B cell receptor specific CD4 T cells
por: Weng, Jinsheng, et al.
Publicado: (2015)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
por: Neelapu, Sattva S, et al.
Publicado: (2020)

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis
por: Chihara, Dai, et al.
Publicado: (2018)

Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma
por: Sarkar, Aloke, et al.
Publicado: (2020)

Platelet activating factor-induced expression of p21 is correlated with histone acetylation
por: Damiani, Elisabetta, et al.
Publicado: (2017)

P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA
por: Strati, Paolo, et al.
Publicado: (2023)

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
por: Gouni, Sushanth, et al.
Publicado: (2022)

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions
por: Pinnix, Chelsea C., et al.
Publicado: (2017)

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
por: Chu, Fuliang, et al.
Publicado: (2023)

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
por: Gunther, Jillian R., et al.
Publicado: (2020)

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
por: Timmerman, John, et al.
Publicado: (2020)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas
por: Sheng Sow, Heng, et al.
Publicado: (2013)

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma
por: Chihara, Dai, et al.
Publicado: (2018)

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2020)

Absence of Grail promotes CD8(+) T cell anti-tumour activity
por: Haymaker, Cara, et al.
Publicado: (2017)

Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare
por: Kim, Sang T., et al.
Publicado: (2019)

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma
por: Strati, Paolo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d07vbkgo8s07cobn1rfa8pc78v